Research programme: Humabody VH antibody fragment-based therapeutics - Crescendo Biologics

Drug Profile

Research programme: Humabody VH antibody fragment-based therapeutics - Crescendo Biologics

Alternative Names: CB 001 - Crescendo Biologics

Latest Information Update: 30 Sep 2016

Price : $50

At a glance

  • Originator Crescendo Biologics
  • Class Immunoglobulin fragments
  • Mechanism of Action CD3 antigen modulators; Immunomodulators; Neoplasm antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Psoriasis
  • Research Cancer

Most Recent Events

  • 28 Sep 2016 Cresendo Biologics has patent protection for Crescendo Mouse platform in USA
  • 02 Jul 2015 Preclinical development is ongoing for Psoriasis and research is ongoing for Cancer in the United Kingdom
  • 02 Jul 2015 Preclinical trials in Psoriasis in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top